U
UniQure
Delivering on the promise of gene therapy - single treatments with potentially curative result for patients with severe genetic diseases.
At a glance
- Status
- Listed
- Founded
- 1998
- Headquarters
- Amsterdam, Netherlands
- Listing
- IPO 2014
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tierThoroughbred$100M+ revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later5 investors entered at this stage
- FPForbion Capital Partners
- CCColler Capital
- AUAmsterdam UMC
- UAUniversity of Amsterdam
- CPChiesi Pharmaceuticals
Source: Dealroom Talent Intelligence.
Alumni founders
Former UniQure employees who went on to found companies, sorted by Dealroom signal score.
NPNewAmsterdam PharmaEst. 2019
Johannes J. P. KasteleinUnited States
VTVectorY TherapeuticsEst. 2020
VAVarmXEst. 2016
Pieter ReitsmaNetherlands
Benjamin BlahaDenmark
FTFrontera TherapeuticsEst. 2019
Yong DaiUnited StatesGlobal footprint
team presence
across markets
Patents
42 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about UniQure on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See UniQure on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

